{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:48:04Z","timestamp":1782841684676,"version":"3.54.5"},"reference-count":48,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Neoadjuvant chemotherapy (NAC) is a crucial component of systemic treatment for triple-negative breast cancer (TNBC), serving as an effective means to reduce recurrence rates and improve survival outcomes. It not only maximizes the extent of resectable tumors but also converts inoperable tumors into operable ones. Shen-Ling-Lian-Xia Granules (SLLXG) is an in-house preparation developed by Longhua Hospital, affiliated with Shanghai University of Traditional Chinese Medicine. Formulated by Professor Liu Sheng, the fifth-generation inheritor of the Shanghai Gu School of Surgery, based on extensive clinical experience treating breast cancer, this compound has been clinically proven to improve postoperative symptoms in patients with TNBC, enhance immunity, reduce recurrence and metastasis, and prolong disease-free survival. However, clinical evidence regarding its efficacy in enhancing the therapeutic effect of NAC for TNBC remains to be established.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aims to analyze the impact of SLLXG on the efficacy of NAC for TNBC, evaluate its synergistic effect on NAC, and identify potential beneficiary populations for SLLXG in treating TNBC. It seeks to establish a standardized diagnostic and treatment protocol for broader clinical implementation.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This study will recruit 306 patients diagnosed with TNBC. Patients will be randomly assigned to two groups: one receiving NAC combined with SLLXG treatment, and the other receiving NAC combined with SLLXG placebo treatment. The primary efficacy endpoint was pathological complete response. Secondary efficacy endpoints included objective response rate, clinical benefit rate, Miller-Payne grading for breast cancer, residual cancer burden, peripheral blood lymphocyte levels, stromal tumor-infiltrating lymphocytes in the tumor region stroma, and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30; version 3.0). Evaluation timepoints will occur after completion of cycles 2, 4, 6, and 8 of NAC. Data will be analyzed using SPSS (version 25.0; IBM Corp) to compare within-group and between-group differences between the 2 cohorts, with a significance level of \u03b1=.05 for hypothesis testing.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study was funded in January 2025 and was approved by the Medical Ethics Committee in October 2025. Patient recruitment is scheduled to commence in February 2026. As of January 2026, no patients have been enrolled. The study is expected to conclude data collection by December 2027, with data analysis and final results anticipated for publication in spring 2028.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The findings of this study will validate the efficacy of SLLXG in treating TNBC and confirm its synergistic effect on treatment outcomes compared to NAC alone.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/91475","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T21:15:09Z","timestamp":1775769309000},"page":"e91475-e91475","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Shen-Ling-Lian-Xia Granule Combined With Neoadjuvant Chemotherapy in Patients With Triple-Negative Breast Cancer: Protocol for a Randomized, Double-Blind, Multicenter Clinical Trial"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1445-3426","authenticated-orcid":false,"given":"Yuanyuan","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8749-5432","authenticated-orcid":false,"given":"Shuai","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-2550","authenticated-orcid":false,"given":"Youyang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8117-7363","authenticated-orcid":false,"given":"Lichen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-2115","authenticated-orcid":false,"given":"Tian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6347-7880","authenticated-orcid":false,"given":"Rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5887-1817","authenticated-orcid":false,"given":"Kaigang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5256-5025","authenticated-orcid":false,"given":"Xiaoqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1437-4156","authenticated-orcid":false,"given":"Jue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2218-1447","authenticated-orcid":false,"given":"Jinhui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3066-5297","authenticated-orcid":false,"given":"Sheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"10512","key":"R1","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0140-6736(25)01635-6","article-title":"The global, regional, and national burden of cancer, 1990\u20132023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"Force","journal-title":"The Lancet"},{"issue":"1","key":"R2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01660-y","article-title":"Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021","volume":"18","author":"Li","journal-title":"J Hematol Oncol"},{"issue":"1","key":"R3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","journal-title":"CA A Cancer J Clinicians"},{"issue":"2","key":"R4","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1016\/S1470-2045(18)30897-0","article-title":"Essential TNM: a registry tool to reduce gaps in cancer staging information","volume":"20","author":"Pi\u00f1eros","journal-title":"Lancet Oncol"},{"issue":"1","key":"R5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.soc.2017.08.004","article-title":"Triple-negative breast cancer: who should receive neoadjuvant chemotherapy?","volume":"27","author":"Chaudhary","journal-title":"Surg Oncol Clin N Am"},{"issue":"12","key":"R6","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","journal-title":"Clin Cancer Res"},{"issue":"24","key":"R7","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1158\/0008-5472.CAN-20-1792","article-title":"Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: a meta-analysis","volume":"80","author":"Huang","journal-title":"Cancer Res"},{"issue":"4","key":"R8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/j.seminoncol.2020.05.006","article-title":"Early stage triple negative breast cancer: management and future directions","volume":"47","author":"Chaudhary","journal-title":"Semin Oncol"},{"issue":"9938","key":"R9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","journal-title":"The Lancet"},{"issue":"3","key":"R10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.5834","article-title":"Response to treatment, racial and ethnic disparity, and survival in patients with breast cancer undergoing neoadjuvant chemotherapy in the US","volume":"6","author":"Shubeck","journal-title":"JAMA Netw Open"},{"issue":"8","key":"R11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","journal-title":"J Clin Oncol"},{"issue":"12","key":"R12","first-page":"7483","volume":"36","author":"Wang","journal-title":"Chin J Tradit Chin Med"},{"issue":"5","key":"R13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.16305\/j.1007-1334.2021.2007017","article-title":"A retrospective cohort study of traditional Chinese medicine Sanyin Formula for triple-negative breast cancer","volume":"55","author":"Xin","journal-title":"Shanghai J Tradit Chin Med"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.850155","article-title":"Effectiveness of the Sanyin Formula plus chemotherapy on survival in women with triple-negative breast cancer: a randomized controlled trial","volume":"12","author":"Wu","journal-title":"Front Oncol"},{"issue":"1","key":"R15","doi-asserted-by":"publisher","DOI":"10.3390\/ph16010009","article-title":"Sanyin Formula enhances the therapeutic efficacy of paclitaxel in triple-negative breast cancer metastases through the JAK\/STAT3 pathway in mice","volume":"16","author":"Wu","journal-title":"Pharmaceuticals (Basel)"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1381251","article-title":"Potential therapeutic targets of the JAK2\/STAT3 signaling pathway in triple-negative breast cancer","volume":"14","author":"Long","journal-title":"Front Oncol"},{"issue":"18","key":"R17","doi-asserted-by":"publisher","first-page":"7391","DOI":"10.1073\/pnas.0609757104","article-title":"Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity","volume":"104","author":"Siddiquee","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"30","key":"R18","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1038\/s41388-024-03084-3","article-title":"Correction: Interaction between STAT3 and GLI1\/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer","volume":"43","author":"Sirkisoon","journal-title":"Oncogene"},{"issue":"6","key":"R19","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1158\/0008-5472.CAN-09-2468","article-title":"Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells","volume":"70","author":"Lin","journal-title":"Cancer Res"},{"issue":"1","key":"R20","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1186\/s12967-025-07370-w","article-title":"Recent progress in immune evasion mechanisms of triple-negative breast cancer","volume":"23","author":"Yang","journal-title":"J Transl Med"},{"issue":"5","key":"R21","first-page":"5017","volume":"8","author":"Wang","journal-title":"Int J Clin Exp Pathol"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081477","article-title":"SPIRIT 2025 statement: updated guideline for protocols of randomised trials","volume":"389","author":"Chan","journal-title":"BMJ"},{"issue":"6","key":"R23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00432-024-05738-x","article-title":"Comparison of the efficacy of taxanes with carboplatin and anthracyclines with taxanes in neoadjuvant chemotherapy for stage II\u2013III triple negative breast cancer: a retrospective analysis","volume":"150","author":"Wang","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"R24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"R25","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1245\/s10434-021-11223-3","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline","volume":"29","author":"Tamirisa","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"R26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1080\/01635581.2025.2480854","article-title":"Vitamin D supplementation improves pathological complete response in breast cancer patients undergoing neoadjuvant chemotherapy: a randomized clinical trial","volume":"77","author":"Omodei","journal-title":"Nutr Cancer"},{"issue":"4","key":"R27","first-page":"1121","volume":"11","author":"Delgado","journal-title":"Am J Cancer Res"},{"issue":"Supplement","key":"R28","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.4103\/ijc.IJC_1417_20","article-title":"Significance of emerging clinical oncology endpoints in support of overall survival","volume":"59","author":"Patil","journal-title":"Indian J Cancer"},{"issue":"2","key":"R29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003302","article-title":"Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival","volume":"10","author":"Manitz","journal-title":"J Immunother Cancer"},{"issue":"1","key":"R30","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00565-8","article-title":"Spatial immunophenotypes orchestrate prognosis in triple-negative breast cancer with Miller-Payne grade 4 following neoadjuvant chemotherapy","volume":"9","author":"Ma","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"R31","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","journal-title":"Lancet Oncol"},{"issue":"15","key":"R32","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1002\/cam4.4666","article-title":"Peripheral blood lymphocytes subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer","volume":"11","author":"Feng","journal-title":"Cancer Med"},{"issue":"1","key":"R33","doi-asserted-by":"publisher","first-page":"21324","DOI":"10.1038\/s41598-023-48300-4","article-title":"Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer","volume":"13","author":"Huertas-Caro","journal-title":"Sci Rep"},{"issue":"1","key":"R34","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12778-6","article-title":"Association of clinicopathologic and sonographic features with stromal tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"24","author":"Hu","journal-title":"BMC Cancer"},{"issue":"12","key":"R35","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50074","article-title":"Major low anterior resection syndrome (lars) and quality of life in patients with low rectal cancer: a preoperative survey using lars score and european organisation for research and treatment of cancer\u2019s 30-item core quality of life questionnaire","volume":"15","author":"Huu Phu","journal-title":"Cureus"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.10.026","article-title":"Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer","volume":"178","author":"Cocks","journal-title":"Eur J Cancer"},{"issue":"9","key":"R37","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"R38","first-page":"1339","volume":"165","author":"Montori","journal-title":"CMAJ"},{"issue":"3","key":"R39","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","volume":"35","author":"O\u2019Brien","journal-title":"Biometrics"},{"issue":"12","key":"R40","doi-asserted-by":"publisher","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","article-title":"National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data","volume":"8","author":"Qi","journal-title":"Lancet Public Health"},{"issue":"10","key":"R41","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s12032-024-02456-9","article-title":"The treatment landscape of triple-negative breast cancer","volume":"41","author":"Hu","journal-title":"Med Oncol"},{"issue":"11","key":"R42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16112012","article-title":"Recent developments in combination immunotherapy with other therapies and nanoparticle-based therapy for triple-negative breast cancer (TNBC)","volume":"16","author":"Battogtokh","journal-title":"Cancers (Basel)"},{"issue":"1","key":"R43","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","journal-title":"Breast Cancer Res"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S426121","article-title":"Research progress on molecular subtyping and modern treatment of triple-negative breast cancer","volume":"15","author":"Tong","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"11","key":"R45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009616","article-title":"Intratumoral and peritumoral radiomics of MRIs predicts pathologic complete response to neoadjuvant chemoimmunotherapy in patients with head and neck squamous cell carcinoma","volume":"12","author":"Lin","journal-title":"J Immunother Cancer"},{"issue":"18","key":"R46","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr1576","article-title":"A multimodal and fully automated system for prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer","volume":"11","author":"Mao","journal-title":"Sci Adv"},{"issue":"8","key":"R47","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.31557\/APJCP.2022.23.8.2749","article-title":"Stromal tumor infiltrating lymphocytes (sTILs) Were Associated with a higher grade and a lower stage of indonesian triple negative breast cancers","volume":"23","author":"Widodo","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"R48","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-11815-8","article-title":"Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer","volume":"24","author":"Gao","journal-title":"BMC Cancer"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e91475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:15:48Z","timestamp":1782839748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e91475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":48,"URL":"https:\/\/doi.org\/10.2196\/91475","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"v15i10512e91475"}}